Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I must admit I’ve been wondering if they’re in a closed period. Just a hunch and I may be wrong
The same thought has occurred to me, because little is being said (and nothing, so far, that is new - despite the ongoing trials etc). There is no obvious reason for them to be in a close period, especially after the raise a few months back - and so I suspect that “things are going on”.
So this is the wording on Modi-1 in latest RNS:
"I am also looking forward to presenting early data from patients receiving Modi-1 as a monotherapy in range of hard-to-treat solid tumours, which has shown good T cell responses, safety and tolerability"
We already knew results from mono-therapy had not been as as good as some had hoped/expected.
Careful avoidance of the combo results though - is this simply because those results are not being presented at the conference and/or possibly are not available yet (in statistically significant numbers at least).
It seems modi-1 has had the desired T-cell outcome, so combined with checkpoints one would hope for a much better efficacy read.
I don't think LD would be presenting modi-1 at all if it was dead in the water.
Its a logical conclusion Burble, and might apply to a number of products.... what would we conclude if they stopped going to these meetings altogether and for no apparent reason? I have had the feeling that something is afoot for a while, if there was a serious problem, they would need to tell us, but if things are going along swimmingly you would asume they would be desperate to tell us, but it appears we are in limbo so you have to ask why?.... NDA is very a possible reason .
Given what was last said about the antibodies, it may well be that one of the five possible deals is now close at hand.
It is also interesting to ponder whether the raise late last year was accelerated, due to an expectation that they would be unable to raise during 2024 due to close periods relating to continuing discussions on multiple fronts (as there very well may be at present, given the two trials and the antibody possibilities). Whatever the cause, I see no reason whatsoever for assuming the hiatus in newsflow is negative - and would take a strong view to the contrary.
Moonparty,
Worth remembering that the combination arm of the Modi1 trial is only recruiting head and neck and renal cancer patients and originally intended to combine with a single checkpoint inhibitor. As at the end of January they were waiting for approval from the MHRA for a protocol amendment to change the setting of the renal cohort from 3rd line to first line and the combination from a single CPI to to the doublet therapy of Opdivo (PD-1) and Yervoy (CTLA4). Assume they are still waiting for this approval from MHRA and therefore not currently recruiting to the renal cancer cohort. So it may well be that they have only been recruiting to the head and neck cohort which means recruitment has been slower than expected. All we know is that as at July last year they had recruited and dosed 3 combination patients to the safety run in cohort 4. We don't know whether any further patients have been recruited since and if so how many.
As for the neoadjuvant study, as at the 30th January they had recruited a total of 2 patients. The first was a monotherapy patient. He/she had been dosed and resected and their tumour was undergoing analysis. A second patient had been recruited to the combination arm and was about to receive his/her first dose. I'm not sure what the interval is between dosing and surgery, perhaps someone else here can tell us, but I expect it's several weeks.
You'll note that all RNSs simply say early data from these arms will be reported in 2024 but I've listened again to the interims webcast and fortunately Lindy is a little more specific. It will be late this year - possibly Q3 but more likely Q4.
Given that they're only recruiting head & neck cancer patients at the moment, I'm pretty certain that there are no hidden reasons (positive or negative) for the lack of combination/neoadjuvant updates - they simply haven't recruited enough patients yet.
Nevertheless I hope that Scancell will at least provide a progress report on recruitment and possibly early safety data. Perhaps they will.
Thanks Troajan,
TLDR:
Reiterating its 'buy' advice and 30p a share price target, the bank said: "We continue to see significant value in Scancell's highly innovative approach to cancer vaccine development.
"We see the next 12 months as a potentially transformative period for the business and view Scancell as an attractive investment at these levels."
Hi Bermuda,
Your 12.26, you ask “I'm not sure what the interval is between dosing and surgery, perhaps someone else here can tell us, but I expect it's several weeks.”
According to the Procedure Chart “Surgery (+ tumour assessment and a blood test to check on activity of immune cells)” is visit day 50 (Though confusingly the chart refers to week 6):-
https://modi-1-neoadj.digitrial.com/steps/7
The previous page (page 6 on the above link) tells us that initial screening can take up to 4 weeks to check that the patient is suitable for the study. It also says “You will also need to come to the clinic approximately 6 weeks after your surgery, for a final assessment.”
So once a patient is accepted onto the study it takes a total of about 92 days until final assessment (50 days plus approximately 6 weeks).
Johnny - thanks for that, appreciated
This release is part of the softening up process to get us to 30p guys. Why? Cause stiflel is theirs.
So when’s it coming?
Six weeks from dosing to surgery was the plan.